M&T Bank Corp Has $471,000 Stake in Repligen Co. (NASDAQ:RGEN)

M&T Bank Corp grew its holdings in Repligen Co. (NASDAQ:RGEN) by 5.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 3,166 shares of the biotechnology company’s stock after acquiring an additional 177 shares during the quarter. M&T Bank Corp’s holdings in Repligen were worth $471,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Andra AP fonden acquired a new stake in Repligen in the 2nd quarter valued at approximately $25,000. International Assets Investment Management LLC acquired a new stake in shares of Repligen in the second quarter worth $33,000. UMB Bank n.a. grew its stake in shares of Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 130 shares during the last quarter. Blue Trust Inc. increased its position in Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares during the period. Finally, Quarry LP raised its stake in Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 239 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Wells Fargo & Company initiated coverage on Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target on the stock. Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Finally, Canaccord Genuity Group started coverage on Repligen in a research note on Tuesday. They issued a “hold” rating and a $165.00 target price for the company. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $185.20.

Repligen Stock Down 1.7 %

Shares of NASDAQ RGEN opened at $158.14 on Wednesday. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The business has a fifty day moving average of $143.15 and a two-hundred day moving average of $141.68. The stock has a market cap of $8.86 billion, a PE ratio of -427.41, a PEG ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the firm posted $0.23 EPS. As a group, equities research analysts expect that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.